Vanda Pharmaceuticals (VNDA) Change in Receivables (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted Change in Receivables of $2.3 million for Q1 2026, down 42.75% sequentially from $4.1 million in Q4 2025, and up 192.07% YoY from $798786.9 in Q1 2025.
Vanda Pharmaceuticals (VNDA) Change in Receivables (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Change in Receivables for 17 years, with the latest figure at $2.3 million in Q1 2026.
- Quarterly Change in Receivables rose 192.07% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.3 million (up 56.25% YoY) and the FY2025 annual result came in at $7.5 million, down 42.65% from the prior year.
- Change in Receivables declined to $2.3 million in Q1 2026 per VNDA's latest filing, from $4.1 million in the prior quarter.
- Over five years, Change in Receivables peaked at $9.1 million in Q2 2023 and troughed at -$8.9 million in Q1 2023.
- A 5-year average of $1.4 million and a median of $2.3 million in 2026 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 662.42% in 2023, down 829.85% in 2023.
- Over 5 years, Change in Receivables stood at $4.1 million in 2022, then rose by 18.79% to $4.8 million in 2023, then fell by 8.37% to $4.4 million in 2024, then fell by 8.03% to $4.1 million in 2025, then plunged by 42.75% to $2.3 million in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $2.3 million, $4.1 million, and $5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | 2.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.80 Mn |
| Jun 30, 2026 | 2.80 Mn |
| Mar 31, 2026 | 2.33 Mn |
| Mar 31, 2026 | 2.33 Mn |
| Dec 31, 2025 | 4.08 Mn |
| Dec 31, 2025 | 4.08 Mn |
| Sep 30, 2025 | 5.57 Mn |
| Sep 30, 2025 | 5.57 Mn |
| Jun 30, 2025 | 353,000.00 |
| Jun 30, 2025 | 353,000.00 |
| Mar 31, 2025 | -2.53 Mn |
| Mar 31, 2025 | -2.53 Mn |
| Dec 31, 2024 | 4.43 Mn |
| Dec 31, 2024 | 4.43 Mn |
| Sep 30, 2024 | 830,000.00 |
| Sep 30, 2024 | 830,000.00 |
| Jun 30, 2024 | 5.16 Mn |
| Jun 30, 2024 | 5.16 Mn |
| Mar 31, 2024 | 2.59 Mn |
| Mar 31, 2024 | 2.59 Mn |